Rapid, Scalable, and Ultra-Sensitive Validation of Allele-Specific Gene Editing Events with genoTYPER-NEXT™
About the Case Study
This case study focuses on a collaboration between Azenta and a large pharmaceutical client to develop a more effective approach for screening engineered cell lines via an automated, interactive NGS-based platform. This powerful technology permits the identification of all classes of genetic disruptions, including mono-allelic, homozygous, and heterozygous biallelic modifications.
For technical support questions, please contact our Next Generation Sequencing team
(877) 436-3949 ext. 1 | firstname.lastname@example.org